IDE161
Tumors with homologous recombination deficiency (HRD)
Phase 1Active
Key Facts
Indication
Tumors with homologous recombination deficiency (HRD)
Phase
Phase 1
Status
Active
Company
About IDEAYA Biosciences
IDEAYA Biosciences is committed to discovering and developing transformative precision oncology therapies by integrating biomarker discovery with targeted therapeutics. The company leverages its expertise in synthetic lethality—an emerging class of targets that exploits cancer-specific genetic vulnerabilities—to create a therapeutic window. Its most advanced programs are in clinical development with key collaborations from Pfizer, Gilead, and GSK, positioning IDEAYA at the forefront of next-generation, biomarker-driven cancer treatments.
View full company profile